<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02442414</url>
  </required_header>
  <id_info>
    <org_study_id>5209-CPK-1001</org_study_id>
    <nct_id>NCT02442414</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sihuan Pharmaceutical Holdings Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>XuanZhu Pharma Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sihuan Pharmaceutical Holdings Group Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose of KBP-5209 as a single
      agent when given orally to adult patients with advanced solid tumors that have progressed
      despite standard therapy, or where there is no standard therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, open-label, multicenter study of KBP-5209 administered orally once daily
      (QD) in 28-day treatment cycles to adult patients with advanced solid tumors which have
      progressed despite standard therapy or for which no standard therapy exists. This study is
      designed to determine the MTD or RP2D and to characterize the safety, tolerability, and PK
      profile of KBP-5209.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Outcome Measure: safety and tolerability, based on the rate of dose-limiting toxicities, toxicity grade, and reversibility of toxicity.</measure>
    <time_frame>2 Years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-dependency of toxicity based on: dose limiting toxicities; frequency, type, grade, and seriousness, and causality of treatment-emergent adverse events, and laboratory assessments.</measure>
    <time_frame>While undergoing study treatment and up to 30 days after the last dose of KBP-5209</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>KBP-5209</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation for KBP-5209 will initially follow a modified accelerated titration design with a starting dose of 20 mg QD. Early dose escalation will proceed with one-patient cohorts and 100% dose increments (ie, dose doubling) until a patient experiences a DLT, at which point the cohorts will move to a 3+3 design. Treatment will continue until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons. A cycle is defined as continuous treatment for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KBP-5209</intervention_name>
    <description>Single oral dose beginning at 20 mg with daily dosing for 28 day cycles.</description>
    <arm_group_label>KBP-5209</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older;

          -  Patients with histologically or cytologically confirmed, advanced solid tumors which
             have progressed despite standard therapy or for whom no standard therapy exists.

          -  Patients must have at least one measurable or non-measurable lesion (dose escalation
             only) as defined by RECIST v1.1

          -  Eastern Cooperative Oncology Group performance score 0 to 2;

        Exclusion Criteria:

          -  Patients with symptomatic CNS metastases;

          -  Patients who have a known history of hepatitis C or chronic active hepatitis B or a
             known diagnosis of HIV

          -  Any significant ophthalmologic abnormality

          -  Patients who have any severe and/or uncontrolled medical conditions

          -  Significant gastrointestinal abnormalities,

          -  Patients who have impaired cardiac function or clinically significant cardiac
             diseases,

          -  Chemotherapy, biologic therapy, immunotherapy, radiotherapy or investigational agents
             within 5 half-lives or within 4 weeks (whichever is longer) prior to administration of
             the first dose of study drug on Day 1 or have not recovered from the side effects of
             such therapy;

          -  Treatment with third generation EGFR inhibitors

          -  Major surgery/surgical therapy for any cause within 4 weeks of Screening;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matthew S Hunt, BA</last_name>
    <phone>608 332 8641</phone>
    <email>Matthew.hunt2@covance.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bert O'Neil</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarina Piha-Paul</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Sharma</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55.</citation>
    <PMID>7165009</PMID>
  </reference>
  <reference>
    <citation>Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst. 1997 Aug 6;89(15):1138-47.</citation>
    <PMID>9262252</PMID>
  </reference>
  <reference>
    <citation>Gibaldi M, Perrier D. Pharmacokinetics. 2nd edition. New York, NY: Marcel Dekker, Inc.; 1982.</citation>
  </reference>
  <reference>
    <citation>ICH E3: Guideline for Industry: Structure and Content of Clinical Study Reports. 1996.</citation>
  </reference>
  <reference>
    <citation>Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, Chaudhuri S, Pujara K, Guillory J, Edgar KA, Janakiraman V, Scholz RP, Bowman KK, Lorenzo M, Li H, Wu J, Yuan W, Peters BA, Kan Z, Stinson J, Mak M, Modrusan Z, Eigenbrot C, Firestein R, Stern HM, Rajalingam K, Schaefer G, Merchant MA, Sliwkowski MX, de Sauvage FJ, Seshagiri S. Oncogenic ERBB3 mutations in human cancers. Cancer Cell. 2013 May 13;23(5):603-17. doi: 10.1016/j.ccr.2013.04.012. Erratum in: Cancer Cell. 2014 Apr 14;25(4):543-4.</citation>
    <PMID>23680147</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2015</study_first_submitted>
  <study_first_submitted_qc>May 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2015</study_first_posted>
  <last_update_submitted>May 8, 2015</last_update_submitted>
  <last_update_submitted_qc>May 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>EGFR</keyword>
  <keyword>HER2</keyword>
  <keyword>HER3</keyword>
  <keyword>HER4</keyword>
  <keyword>ALK mutations</keyword>
  <keyword>irreversible tyrosine kinase inhibitor</keyword>
  <keyword>Metastatic Non Small Cell Lung Cancer</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Colorectal Cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

